Bextra, Vioxx & Celebrex FDA Transcript
Your lawyer provides you with the complete transcript of the February 17th, 2005 joint meeting of the FDA's Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee.
We have formatted the complete transcript of the three day conference for easy of navigation to provide you with the best possible Bextra information. To contact a Bextra Lawyer, click here for a FREE case evaluation.
Contents:
Call to Order:
Alastair J.J. Wood, M.D., Chair
Conflict of Interest
Statement:
Kimberly Littleton Topper, M.S.
Interpretation of
Observational Studies of Cardiovascular Risk of Non-steroidal Drugs
Richard Platt, M.D., M.S.
Review of
Epidemiologic Studies on Cardiovascular Risk with Selected NSAIDs
David
Graham, M.D., M.P.H.
Committee Questions to Speakers
Arcoxia (etoricoxib):
Merck Research Laboratories - Sponsor Presentation
Sean P. Curtis, M.D.
FDA Presentation
Joel Schiffenbauer, M.D.
Lumiracoxib: Novartis
Pharmaceuticals - Sponsor Presentation
Introduction
Mathias
Hukkelhoven, Ph.D.
Gastrointestinal and
Cardiovascular Safety of Lumiracoxib, Ibuprofen, and Naproxen
Patrice
Matchaba, M.D.
FDA Presentation
(Lumiracoxib)
Lourdes Villalba, M.D.
Committee Questions to Speakers
|
Weitz & Luxenberg is no longer accepting Bextra cases.
see also:
Arcoxia (etoricoxib)
Your Bextra Side Effects Lawyer - Vioxx, Celebrex & Bextra FDA - Arcoxia (etoricoxib)Bextra side effects lawyer - the complete transcript of the FDA meeting
Questions
Your Bextra Side Effects Lawyer - Vioxx, Celebrex & Bextra FDA - QuestionsBextra side effects lawyer - the complete transcript of the FDA meeting
Letters
FDA Bextra Letters - Without a Bextra recall, Bextra is still deadlyThough no Bextra recall, Bextra, these letters show, can be dangerous.
